Fresenius Majority-Owned Group Mabxience Has Licensing Agreement With Intas Pharmaceuticals for Autoimmune Disease Drug Etanercept
Portfolio Pulse from Charles Gross
Intas Pharmaceuticals Ltd. has entered into an exclusive licensing agreement with mAbxience, a Fresenius Kabi majority-owned group, for the commercialization of a biosimilar for Etanercept, a drug used to treat autoimmune diseases. The agreement grants Intas rights to commercialize the biosimilar in over 150 countries. mAbxience will handle development, manufacturing, and supply. The deal is expected to strengthen Intas's global biosimilar portfolio and improve access to autoimmune disease treatments worldwide.
December 20, 2023 | 10:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Fresenius Kabi's majority-owned group mAbxience has entered into a licensing agreement with Intas Pharmaceuticals for the Etanercept biosimilar, which could potentially enhance Fresenius's market presence in the biosimilar space and contribute to future revenue streams.
The licensing agreement is directly related to Fresenius's business through its majority-owned group mAbxience. The deal could lead to increased revenues and market share in the biosimilar market, which is significant given the $11B global sales figure for Etanercept. The impact is likely positive in the short term as it reflects growth and expansion in Fresenius's portfolio.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80